16583-17-8

Basic information

• Product Name: 1-cyclopentyl-1-hydroxy-1-phenyl propyne
• Synonyms: 1-cyclopentyl-1-hydroxy-1-phenyl propyne
• CAS NO: 16583-17-8
• Molecular Weight: 200.28
• Mol File: 16583-17-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-cyclopentyl-1-hydroxy-1-phenyl propyne(CAS DataBase Reference)
• NIST Chemistry Reference: 1-cyclopentyl-1-hydroxy-1-phenyl propyne(16583-17-8)
• EPA Substance Registry System: 1-cyclopentyl-1-hydroxy-1-phenyl propyne(16583-17-8)

Safety Data

• Hazardous Substances Data: 16583-17-8(Hazardous Substances Data)

Upstream product

• 5422-88-8 phenyl cyclopentyl ketone 
• 70277-75-7 lithium acetylide 
• 74-86-2 acetylene 

Downstream Products

• 881098-00-6 1-cyclopentyl-1-acetoxy-1-phenyl-2-propanone 
• 16629-67-7 1-Phenyl-1-cyclopentyl-1-methoxy-4-diethylamino-butin-⁽²⁾ 
• 119497-31-3 1-cyclopentyl-1-phenyl-1-hydroxy-7-diethylaminohept-5-yn-2-one 
• 136721-97-6 1-Cyclopentyl-1-hydroxy-1-phenyl-7-dimethylaminohept-5-yn-2-one 
• 146561-91-3 1-cyclopentyl-1-hydroxy-1-phenyl-2-propanone 
• 16583-18-9 1-Phenyl-1-cyclopentyl-1-methoxy-propin-⁽²⁾ 
• 16628-44-7 1-Phenyl-1-cyclopentyl-4-methyl-4-dimethylamino-pentin-⁽²⁾-ol-⁽¹⁾ 

Relevant articles and documents

MUSCARINIC RECEPTOR ANTAGONISTS

This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepration of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.

Analogues of oxybutynin. Synthesis and antimuscarinic and bladder activity of some substituted 7-amino-1-hydroxy-5-heptyn-2-ones and related compounds

Oxybutynin chloride [4-(diethylamino)-2-butynyl α-cyclohexyl-α-hydroxybenzeneacetate hydrochloride, Ditropan] is widely used for the relief of symptoms in neurogenic bladder. This is a result of its combined anticholinergic, antispasmodic, and local anesthetic activities. In a study directed toward development of agents possessing the beneficial properties of oxybutynin, but having a longer duration of action, a series of metabolically more stable keto analogues of the parent ester, i.e. substituted 7-amino-1-hydroxy-5-heptyn-2-ones along with some analogues and derivatives, was prepared and evaluated for in vitro and in vivo antimuscarinic action in guinea pig preparations. Several members of the series were potent antimuscarinics having a longer duration of activity than that of oxybutynin in a guinea pig cystometrogram model. On the basis of its in vitro and in vivo antimuscarinic activity, coupled with a 5-fold greater duration of action than that of oxybutynin, 1-cyclobutyl-7-(dimethylamino)-1-hydroxy-1-phenyl-5-heptyn-2-one (14b) was selected for clinical evaluation.